Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Women with severe morning sickness who take antihistamines more likely to experience bad outcomes

11.06.2013
Women with a severe form of morning sickness who take antihistamines to help them sleep through their debilitating nausea are significantly more likely to experience adverse pregnancy outcomes, including low birth weight babies and premature births, a UCLA study has found.

The findings, the first to link antihistamine use to adverse pregnancy outcomes, are important because babies born before 37 weeks often are hospitalized longer than full term babies, can experience problems breathing and feeding, are more prone to infection and can suffer from developmental problems.

Women with this condition considering taking such medications should know the risks, said study lead author Marlena Fejzo, an assistant professor of research in obstetrics and gynecology at UCLA.

The severe morning sickness, called hyperemesis gravidarum (HG), is the same condition that Duchess Kate Middleton recently experienced. Its cause is unknown and the symptoms are intense - the continuous nausea and vomiting can be so violent that women in the study reported suffering from detached retinas, blown eardrums, cracked ribs and torn esophagi, Fejzo said. The symptoms can last for several months or the entire pregnancy.

"It was surprising to find the link between antihistamines and adverse outcomes as these are over-the-counter medications that are used commonly by women with HG during pregnancy," said Fejzo, who had undiagnosed HG during her first pregnancy and nearly died during her second, losing the baby at 15 weeks gestation. "Women and their healthcare providers should be aware of the risk for adverse outcomes when deciding which medications to take to treat their HG symptoms."

The study appears June 10, 2013 in the European Journal of Obstetrics and Gynecology and Reproductive Biology.

The six-year study compared pregnancy outcomes in 254 women with HG who were sick enough that they needed treatment for dehydration with intravenous fluids to 308 women who had normal or no morning sickness during pregnancy. Fejzo said they found women with HG had four times the risk of adverse outcomes. The link between HG and adverse outcomes has been shown in several previous studies.

Fejzo took it a step farther, comparing women with HG who suffered adverse outcomes to women with HG who had good outcomes. They then looked at more than 35 medications and treatments commonly used by women with HG to determine if any were linked to bad outcomes. She found that antihistamines, like those found in Unisom and Benadryl, were taken by more than 50 percent of HG patients who experienced adverse outcomes.

Fejzo also found that the medications were reportedly effective in less than 20 percent of the women that took them.

"Some doctors will suggest that their HG patients take Unisom to help them sleep through their nausea," Fejzo said. "Our findings show not only that the use of antihistamines is linked with adverse outcomes, but also that they're not that effective. Women with HG should be aware of that so they can make educated decisions on how to treat their HG symptoms."

Adrienne Downs of Culver City experienced some nausea and vomiting during her first two pregnancies, but nothing out of the ordinary. Her third pregnancy was not so run-of-the-mill. She soon began suffering from constant nausea, vomiting around the clock every 20 minutes or so. She was hospitalized twice, five days each time, to get intravenous fluids to treat her severe dehydration and malnutrition.

"I literally could keep nothing down for months," said Downs. "I couldn't even get up out of bed and take care of my family. It was horrible. I was very scared for my baby. How would it get any nutrition if I couldn't eat or drink?"

Downs lost 12 pounds in three weeks early in her pregnancy. Her mother had to move in to take care of Downs' sons, 4 and 2, and try to find something her daughter could keep in her system. Now at 21 weeks gestation, Downs' symptoms have subsided somewhat, although she still can only keep down fluids. She had gained back some of the weight she lost.

Downs said she did not take antihistamines to treat her HG symptoms, but she said the findings are important.

"As pregnant moms, we want to be the best 'house' for our babies that we can," she said. "I had never heard of this condition before I got it, so I'm glad that UCLA researchers are studying HG and may one day find the cause."

Fejzo said HG is diagnosed in 0.2 to 2 percent of pregnant women, although rates are higher in China. She said much more work needs to be done to study the short- and long-term outcomes of medication use during pregnancy.

She and her team currently are studying outcomes in HG pregnancies to determine if the violent nausea and vomiting have any effects on the children later in life.

"We desperately need support for research into HG to determine its cause so that medications can be designed that are safe and effective," Fejzo said. "The greatest risk factor for HG other than a previous HG pregnancy is having a sister who had HG, which increases the risk by 17-fold. This suggests a genetic component is at work."

Fejzo and her team are collecting saliva from women with HG and women with normal pregnancies and are studying the DNA extracted from the saliva to look for genes that may predispose women for HG. She hopes once a cause is discovered, drugs can be developed to either prevent or more effectively treat the condition.

The study was funded by the Hyperemesis Education and Research Foundation.

Kim Irwin | EurekAlert!
Further information:
http://www.mednet.ucla.edu

Further reports about: HG symptoms UCLA antihistamines morning sickness pregnancy outcome

More articles from Health and Medicine:

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht On track to heal leukaemia
18.01.2017 | Universitätsspital Bern

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

New Study Will Help Find the Best Locations for Thermal Power Stations in Iceland

19.01.2017 | Earth Sciences

Not of Divided Mind

19.01.2017 | Life Sciences

Molecule flash mob

19.01.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>